课题基金 / 基金详情

In Vitro and In Vivo screening of chemopreventive agents

In Vitro and In Vivo screening of chemopreventive agents
化学预防剂的体外和体内筛选
批准号：
8151542
负责人：
Steven M Lipkin
金额：
$270.21万
依托单位：
STRANG CANCER PREVENTION CENTER
依托单位国家：
美国
项目类别：
财政年份：
2004
资助国家：
美国
项目状态：
已结题
起止时间：
2004-04-30 至 2011-04-29
来源：
https://reporter.nih.gov/project-details/8151542
关键词：
AgreementAnimal ModelAnimalsArtsBiological AssayBiological ModelsCancer ControlCell Culture TechniquesChemopreventive AgentDivision of Cancer PreventionIn VitroMalignant NeoplasmsModelingMonitorMusNormal tissue morphologyOrgan Culture TechniquesPreventiveScreening procedureWorkbasecancer preventionchemical carcinogendesignin vivoinsightmanmutant mouse modeltumortumor progression

项目摘要

项目成果

Steven M Lipkin的其他基金

相似基金

相关文献

中文摘要
翻译
本主协议提案旨在建立和确定最熟练的化学预防剂和条件，将抑制，逆转或延缓癌症。本总协议提案下的工作是在NCI癌症预防司（DCP）的协调下进行的，使用最先进的、基于机制的模型，这样就可以获得关于人类癌症预防和控制的见解。该提案将提供基于机制的体外和体内试验中潜在癌症预防剂的筛选和鉴定。
英文摘要
This Master Agreement proposal is designed to establish and identify the most proficent chemopreventive agent and conditions that will inhibit, reverse or delay cancer. The work under this master agreement proposal is carried out in coordination with the NCI, in the Division of Cancer Prevention (DCP), using state of the art , mechanism-based models, such that insight may be gained about cancer prevention and control in man. The proposal will provide screening and identification of potential cancer preventive agents in mechanism-based in vitro and in vivo assays.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Lynch Vaccine
CAP-IT CRI U54 ADMINISTRATIVE CORE
Cancer Immune-Interception for Lynch Syndrome
Cancer Immune-Interception for Lynch Syndrome
海外基金